This section has been archived. The COVID-19 Treatment Guidelines Panel will no longer be updating the information found here.
Table 5e. Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors: Selected Clinical Data
Last Updated: March 24, 2022
The clinical trials described in this table do not represent all the trials that the Panel reviewed while developing the recommendations for GM-CSF inhibitors. The studies summarized below are those that have had the greatest impact on the Panel’s recommendations.
The information in this table may include data from preprints or articles that have not been peer reviewed. This section will be updated as new information becomes available. Please see ClinicalTrials.gov for more information on clinical trials that are evaluating GM-CSF inhibitors.
Table 5e. Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors: Selected Clinical Data | |
---|---|
References
- Temesgen Z, Burger CD, Baker J, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a Phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2021. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34863332.
- Temesgen Z, Kelley CF, Cerasoli F, et al. C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial. Thorax. 2022. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35793833.
- Cremer PC, Abbate A, Hudock K, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3(6):e410-e418. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33754144.
- Patel J, Beishuizen A, Ruiz X, et al. A randomized trial of otilimab in severe COVID-19 pneumonia (OSCAR). medRxiv. 2021;Preprint. Available at: https://www.medrxiv.org/content/10.1101/2021.04.14.21255475v1.